NRG-GY033

Closed

Return to Protocol Table

A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in combination with Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumors

Principal Investigator

Elizabeth Hopp, MD,

Status

Closed

Date Opened To Accrual

January 22 2024

Date Closed to Accrual

April 25 2025

Disease Site

Gynecologic [GY]

Ovarian

Phase

Developmental Therapeutics

Primary Objective

To determine the objective response rate of darolutamide, leuprolide acetate, and exemestane in recurrent adult-type granulosa cell tumors of the ovary (AGCT).

Patient Population

Patients with recurrent ovarian granulosa cell tumors

Target Accrual

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Other

NRG-GY033 Study Overview by Dr. Libby Hopp

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.